resistant  bacteria  had  a  9-fold  (OR  9.83%)  risk  for 
resistance  to  at  least  4  β-lactam  and  non-β-lactam 
antibiotics  (erythromycin,  tetracycline, 
chloramphenicol,  gentamicin,  ofloxacin,  or 
trimethoprim-sulfamethoxazole). (Cadilla, 2013) 
Fusidic  acid  has  a  unique  and  very  different 
chemical structure. The carbon chains in the chemical 
structure  of  fusidic  acid  are similar  to  steroids  than 
antibiotics so rarely  cause cross-resistance
10
. The in 
vitro  efficacy  of  antibiotics  is  more  significant  if 
proven to be in vivo. In vitro sensitivity is not entirely 
predictable  for  in vivo  effect.  In  addition,  in vitro 
resistance is common, but not necessarily related to 
treatment failure
 
(McNeil,2014) 
5  CONCLUSION 
The results of this study showed that there has been 
in vitro  resistance  of  S. aureus and S. pyogenes to 
mupirocin. In addition, S. aureus and S. pyogenes are 
more  susceptible  to  fusidic  acid  than  mupirocin.  In 
vitro  effectivity  of  fusidic  acid  was  better  than 
mupirocin. The emergence of resistance in this study 
is influenced by various factors, especially the use of 
antibiotics  that  causes  cross  resistance  between 
bacterial carrier resistant genes.  
ACKNOWLEDGEMENTS 
The  authors  would  like  to  thank  Dr.  dr.  M. 
Zulkarnain, ScPKK and dr. Lisa Dewi, M. KEs who 
assist in the effort of this research. The authors also 
would  like  to  Department  of  Dermatology  and 
Venereology, and Faculty of Medicine of Sriwijaya 
University. 
REFERENCES 
Antonov  NK,  Garzon  MC,  Morel KD,  Whittier  S, Planet 
PJ,  Lauren  CT.  2015.    High prevalence of mupirocin 
resistance in Staphylococcus aureus isolates from a 
pediatric population. AAC; 59(6): 3350-56. 
Cadilla  A,  David  MZ,  Daum  RS,  Vavra  SB.  2011. 
Methicillin-resistant of high-level mupirocin resistance 
and Multidrug-resistant Staphylococcus aureus at an 
Academic Center in the Midwestern United States.  J 
Clin Microbiol; 49(1): p. 95-100. 
Caft  N.  2012.  Superficial cutaneous infections and 
pyodermas.. In: Goldsmith LA, Katz SI, Gilchrest BA, 
Paller  AS,  Leffell  DJ,  Wolff  K,  editors.  Fitzpatrick’s 
Dermatology in General Medicine. 8
th
 ed. New York: 
The Mc Graw-Hill Companies, Inc;. p. 2128-60. 
Depari LI, Sugiri U, Ilona L. 2016.  Relation between risk 
factors of pyoderma and pyoderma incidence.  AMJ; 
3(3): 434-39. 
Karimkhani C, Boyers LN, Prescott L, Weich V, Delamere 
FM,  Nasser  MZ,  et  al.  2014.  Global burden of skin 
sisease as reflected in Cochrane database of systematic 
riview. JAMA Dermatol; 150(9): 945-51. 
Koning S, Van Der Sande R, Venagen AP, Van Suijlekom-
Smit  LWA,  Morris  AD,  Butler  CC,  et  al.2012. 
Intervention of Impetigo (review). Cochrane Database 
Systematic Review issue 1. Amsterdam: John Wiley & 
Sons. 
McNeil  JC,  Hulten  KG,  Kaplan  SL,  Mason  EO.  2014. 
Decreased susceptiblities to ratapamulin, mupirocin, 
and chlorhexidine among Staphylococcus aureus 
isolates causing skin and soft tissue infections in 
otherwise healthy children. Antimicrob Agents Chem; 
58(5): 2878-83.  
Milet CR, Halpern AV, Reboli AC, Heymann WR. 2012. 
Bacterial diseases. In: Bolognia Jl, Jorizzo JL, Rapini 
RP,  Schaver  JV,  editors.  Dermatology.  3
rd
 ed. 
Edinburg: Mosby;  p. 1887-1220. 
Mohajeri  P,  Ghalamine  B,  Rexaei  M,  Khamisabadi  Y. 
2012. Frequency of mupirocin resistant Staphylococcus 
aureus strains isolated from nasal carriers in hospital 
in Kermanshah. Jundisphapus J Microbiol; 5(4):  560-
63. 
Nirwati H, Radiono S, Ariwibowo L, Hananta IPY, Tama 
LGY, Danarti R. 2013. Sensitivity pattern of S. aureus 
isolated from children with pyoderma againts various 
antibiotics in Waingapu, Sumba Nusa Tenggara Timur. 
In:  Nirwati  H,  Dewi  NYA.  Proceeding  of  DAAD-
IGHEP  Maternal  and  Child  Health  Summer  School. 
Bali: Udayana University Press; p. 195-203. 
Paudel  U,  Parajuli  S,  Pokhrel  DB.  2013.  Clinico-
bacteriological profile and antibiotic sensitivity pattern 
in pyodermas: a hospital based study.  Nep  J  Lepr; 
11(1): 49-58. 
Poovelikunnel  T,  Gethin  G,  Humphreys  H.  2015. 
Mupirocin resistance: clinical implications and 
potential alternatives for the eradication of MRSA.  J 
Antimicrob chem; 70: 2681-92. 
 
Sanchez  CE,  Moore  LSP,  Husson  F,  Holmes  AH.  2016. 
What are the factors driving antimicrobial resistance? 
Perspective from a public event in London, England. 
BMC infec Dis; 16(465): 1-5.